Ocular Therapeutix (OCUL) Revenue & Revenue Breakdown
Ocular Therapeutix Revenue Highlights
Latest Revenue (Y)
$58.44M
Latest Revenue (Q)
$14.71M
Main Segment (Y)
Product revenue, net
Ocular Therapeutix Revenue by Period
Ocular Therapeutix Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $58.44M | 13.49% |
| 2022-12-31 | $51.49M | 18.32% |
| 2021-12-31 | $43.52M | 150.08% |
| 2020-12-31 | $17.40M | 311.71% |
| 2019-12-31 | $4.23M | 112.41% |
| 2018-12-31 | $1.99M | 3.48% |
| 2017-12-31 | $1.92M | 1.91% |
| 2016-12-31 | $1.89M | 7.83% |
| 2015-12-31 | $1.75M | 126.68% |
| 2014-12-31 | $772.00K | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2012-12-31 | $10.00K | - |
Ocular Therapeutix generated $58.44M in revenue during NA 2023, up 13.49% compared to the previous quarter, and up 2936.83% compared to the same period a year ago.
Ocular Therapeutix Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $14.71M | -0.59% |
| 2023-12-31 | $14.80M | -0.99% |
| 2023-09-30 | $14.95M | -1.55% |
| 2023-06-30 | $15.19M | 13.55% |
| 2023-03-31 | $13.37M | -4.99% |
| 2022-12-31 | $14.08M | 17.64% |
| 2022-09-30 | $11.96M | -2.45% |
| 2022-06-30 | $12.27M | -6.98% |
| 2022-03-31 | $13.19M | 7.14% |
| 2021-12-31 | $12.31M | 1.28% |
| 2021-09-30 | $12.15M | 3.71% |
| 2021-06-30 | $11.72M | 59.60% |
| 2021-03-31 | $7.34M | -0.10% |
| 2020-12-31 | $7.35M | 25.07% |
| 2020-09-30 | $5.88M | 274.51% |
| 2020-06-30 | $1.57M | -39.86% |
| 2020-03-31 | $2.61M | 15.65% |
| 2019-12-31 | $2.26M | 172.14% |
| 2019-09-30 | $829.00K | 27.54% |
| 2019-06-30 | $650.00K | 32.11% |
| 2019-03-31 | $492.00K | -2.38% |
| 2018-12-31 | $504.00K | 1.20% |
| 2018-09-30 | $498.00K | -23.15% |
| 2018-06-30 | $648.00K | 90.59% |
| 2018-03-31 | $340.00K | -30.18% |
| 2017-12-31 | $487.00K | -6.88% |
| 2017-09-30 | $523.00K | 19.41% |
| 2017-06-30 | $438.00K | -7.79% |
| 2017-03-31 | $475.00K | -7.05% |
| 2016-12-31 | $511.00K | 7.13% |
| 2016-09-30 | $477.00K | 8.16% |
| 2016-06-30 | $441.00K | -3.71% |
| 2016-03-31 | $458.00K | 5.05% |
| 2015-12-31 | $436.00K | 1.63% |
| 2015-09-30 | $429.00K | -6.54% |
| 2015-06-30 | $459.00K | 7.75% |
| 2015-03-31 | $426.00K | -15.64% |
| 2014-12-31 | $505.00K | 253.15% |
| 2014-09-30 | $143.00K | 47.42% |
| 2014-06-30 | $97.00K | 259.26% |
| 2014-03-31 | $27.00K | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Ocular Therapeutix generated $14.71M in revenue during Q1 2024, up -0.59% compared to the previous quarter, and up 104.54% compared to the same period a year ago.
Ocular Therapeutix Revenue Breakdown
Ocular Therapeutix Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 18 |
|---|---|---|---|
| Collaboration revenue | $573.00K | $1.04M | - |
| Product revenue, net | $57.87M | - | - |
| Product | - | $50.46M | $1.99M |
Ocular Therapeutix's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product revenue, net (99.02%), and Collaboration revenue (0.98%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $59.00K | $125.00K | $131.00K | $157.00K | $160.00K | $173.00K | $52.00K | $122.00K | $689.00K | - | - | - | - |
| Product revenue, net | $14.71M | $42.92M | $14.95M | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | $15.03M | $13.21M | $13.90M | $11.91M | $12.14M | $12.50M | $504.00K | $498.00K | $648.00K | $340.00K |
Ocular Therapeutix's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product revenue, net (99.60%), and Collaboration revenue (0.40%).
Ocular Therapeutix Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| OCUL | Ocular Therapeutix | $58.44M | $14.71M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ACHL | Achilles Therapeutics | - | - |
OCUL Revenue FAQ
What is Ocular Therapeutix’s yearly revenue?
Ocular Therapeutix's yearly revenue for 2023 was $58.44M, representing an increase of 13.49% compared to 2022. The company's yearly revenue for 2022 was $51.49M, representing an increase of 18.32% compared to 2021. OCUL's yearly revenue for 2021 was $43.52M, representing an increase of 150.08% compared to 2020.
What is Ocular Therapeutix’s quarterly revenue?
Ocular Therapeutix's quarterly revenue for Q1 2024 was $14.72M, a -0.59% decrease from the previous quarter (Q4 2023), and a 10.03% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $14.8M, a -0.99% decrease from the previous quarter (Q3 2023), and a 5.16% increase year-over-year (Q4 2022). OCUL's quarterly revenue for Q3 2023 was $14.95M, a -1.55% decrease from the previous quarter (Q2 2023), and a 24.95% increase year-over-year (Q3 2022).
What is Ocular Therapeutix’s revenue growth rate?
Ocular Therapeutix's revenue growth rate for the last 3 years (2021-2023) was 34.28%, and for the last 5 years (2019-2023) was 1282.61%.
What are Ocular Therapeutix’s revenue streams?
Ocular Therapeutix's revenue streams in c 23 are Collaboration revenue, and Product revenue, net. Collaboration revenue generated $573K in revenue, accounting 0.98% of the company's total revenue, down -44.74% year-over-year. Product revenue, net generated $57.87M in revenue, accounting 99.02% of the company's total revenue
What is Ocular Therapeutix’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Ocular Therapeutix was Product revenue, net. This segment made a revenue of $57.87M, representing 99.02% of the company's total revenue.